We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQVIA Earnings & Revenues Beat Estimates in Q2, Rise Y/Y
Read MoreHide Full Article
Key Takeaways
IQV's Q2 adjusted EPS rose 6.4% y/y to $2.81 on $4B in revenues, both beating estimates.
Technology and Analytics revenues climbed 8.9% to $1.6B, and Contract Sales rose 9.3% to $188M.
IQV raised 2025 EPS and revenue outlook but trimmed the adjusted EBITDA guidance from the prior quarter.
IQVIA Holdings Analytics Inc. (IQV - Free Report) has reported impressive second-quarter 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate.
Adjusted earnings were $2.81 per share, beating the Zacks Consensus Estimate by 1.8% and rising 6.4% on a year-over-year basis. Total revenues of $4 billion surpassed the consensus estimate by 1.5% and grew 5.3% from the year-ago quarter.
The IQV stock has lost 14.3% in the year-to-date period compared with the 30% decline of the industry it belongs to and against the 6.5% rise of the Zacks S&P 500 Composite.
IQVIA Holdings Inc. Price, Consensus and EPS Surprise
The Research and Development segment’s revenues were $2.2 billion, rising 2.5% from the year-ago quarter and 1.3% on a constant-currency basis. The metric met our estimate.
Revenues from the Technology and Analytics segment were $1.6 billion, increasing 8.9% from the year-ago quarter and 6.8% on a constant-currency basis. The metric met our estimated figure.
Contract Sales and Medical Solutions revenues increased 9.3% on a year-over-year basis to $188 million and increased 6.4% on a constant-currency basis. The metric surpassed our estimation of $181.9 million.
Adjusted EBITDA for the second quarter of 2025 was $910 million, up 2.6% from the year-ago quarter and beating our projection of $899.4 million.
The company exited the quarter with cash and cash equivalents of $2 billion compared with $1.7 billion in the preceding quarter. Long-term debt (less current portion) was $15.5 billion compared with $13.1 billion at the end of the first quarter of 2025.
Net cash generated from operating activities was $443 million and the capital expenditure for the quarter was $151 million. The company generated a free cash flow of $292 million in the quarter.
IQV’s 2025 Guidance
For 2025, IQVIA has updated its revenue guidance to $16.10-$16.30 billion from the $16.00-$16.40 billion provided in the preceding quarter. The guided range is higher than the Zacks Consensus Estimate for revenues of $16.06 billion.
IQVIA’s adjusted EBITDA view was lowered to $3.75-$3.825 billion from the preceding quarter’s view of $3.76-$3.88 billion.
The company has updated its adjusted EPS guidance to $11.75-$12.05 from the preceding quarter’s view of $11.70-$12.10. The mid-point ($11.90) of the guided range is higher than the Zacks Consensus Estimate for earnings of $11.84.
ABM’s EPS (excluding 19 cents from non-recurring items) was 86 cents, which missed the Zacks Consensus Estimate by 1.2% and declined 1.2% year over year. Total revenues of $2.1 billion surpassed the consensus mark by 2.2% and increased 4.6% from the year-ago quarter.
ACN’s earnings were $3.49 per share, beating the Zacks Consensus Estimate by 5.8%. The metric increased 11.5% from the year-ago quarter. Total revenues of $17.7 billion beat the consensus estimate by 2.6% and rose 7.7% on a year-over-year basis.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IQVIA Earnings & Revenues Beat Estimates in Q2, Rise Y/Y
Key Takeaways
IQVIA Holdings Analytics Inc. (IQV - Free Report) has reported impressive second-quarter 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate.
Adjusted earnings were $2.81 per share, beating the Zacks Consensus Estimate by 1.8% and rising 6.4% on a year-over-year basis. Total revenues of $4 billion surpassed the consensus estimate by 1.5% and grew 5.3% from the year-ago quarter.
The IQV stock has lost 14.3% in the year-to-date period compared with the 30% decline of the industry it belongs to and against the 6.5% rise of the Zacks S&P 500 Composite.
IQVIA Holdings Inc. Price, Consensus and EPS Surprise
IQVIA Holdings Inc. price-consensus-eps-surprise-chart | IQVIA Holdings Inc. Quote
IQVIA’s Quarterly Details
The Research and Development segment’s revenues were $2.2 billion, rising 2.5% from the year-ago quarter and 1.3% on a constant-currency basis. The metric met our estimate.
Revenues from the Technology and Analytics segment were $1.6 billion, increasing 8.9% from the year-ago quarter and 6.8% on a constant-currency basis. The metric met our estimated figure.
Contract Sales and Medical Solutions revenues increased 9.3% on a year-over-year basis to $188 million and increased 6.4% on a constant-currency basis. The metric surpassed our estimation of $181.9 million.
Adjusted EBITDA for the second quarter of 2025 was $910 million, up 2.6% from the year-ago quarter and beating our projection of $899.4 million.
The company exited the quarter with cash and cash equivalents of $2 billion compared with $1.7 billion in the preceding quarter. Long-term debt (less current portion) was $15.5 billion compared with $13.1 billion at the end of the first quarter of 2025.
Net cash generated from operating activities was $443 million and the capital expenditure for the quarter was $151 million. The company generated a free cash flow of $292 million in the quarter.
IQV’s 2025 Guidance
For 2025, IQVIA has updated its revenue guidance to $16.10-$16.30 billion from the $16.00-$16.40 billion provided in the preceding quarter. The guided range is higher than the Zacks Consensus Estimate for revenues of $16.06 billion.
IQVIA’s adjusted EBITDA view was lowered to $3.75-$3.825 billion from the preceding quarter’s view of $3.76-$3.88 billion.
The company has updated its adjusted EPS guidance to $11.75-$12.05 from the preceding quarter’s view of $11.70-$12.10. The mid-point ($11.90) of the guided range is higher than the Zacks Consensus Estimate for earnings of $11.84.
IQV carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Earnings Snapshot of Peers
ABM (ABM - Free Report) reported mixed second-quarter fiscal 2025 results.
ABM’s EPS (excluding 19 cents from non-recurring items) was 86 cents, which missed the Zacks Consensus Estimate by 1.2% and declined 1.2% year over year. Total revenues of $2.1 billion surpassed the consensus mark by 2.2% and increased 4.6% from the year-ago quarter.
Accenture plc (ACN - Free Report) posted impressive third-quarter fiscal 2025 results.
ACN’s earnings were $3.49 per share, beating the Zacks Consensus Estimate by 5.8%. The metric increased 11.5% from the year-ago quarter. Total revenues of $17.7 billion beat the consensus estimate by 2.6% and rose 7.7% on a year-over-year basis.